Archive news

Together with world-renowned scientists including Prof. Joel F. Habener, Prof. Jens Juul Holst and Assoc. Prof. Svetlana Mojsov, Prof. Daniel Drucker at the University of Toronto and the Lunenfeld-Tanenbaum Research Institute, has discovered the role of glucagon-like peptide-1 (GLP-1), leading to life-changing therapies for people with diabetes and obesity while stimulating emerging applications for neurodegenerative diseases. This groundbreaking innovation has garnered significant recognition for him and the GLP-1 research group, exemplified by the prestigious 2023 VinFuture Special Prize for Innovators with Outstanding Achievements in Emerging Fields, and the 2025 Breakthrough Prize in Life Sciences, awarded earlier this April. In this interview, he reflects on the impact and influences of the VinFuture Prize on his further research, as well as the challenges and prospects of expanding GLP-1 accessibility. As global scientific recognition continues to evolve, he shares insights into the vital role of initiatives like the VinFuture Prize in inspiring the next generation of scientists.

In this episode, we explore the dynamic realm of artificial intelligence and robotics, a field poised to revolutionize industries and societies. With robotics projected to become a multi-billion dollar market in the coming decade, we are honored to welcome a luminary in the field - Professor Daniela Rus, Director of the Computer Science and Artificial Intelligence Laboratory (CSAIL) at the Massachusetts Institute of Technology (USA) - to share her insights on the prospects of this revolution. 

The 2023 VinFuture Special Prize Laureates have just been honored with the 2025 Breakthrough Prize in Life Sciences for their pioneering work in uncovering the role of GLP-1 hormones - the foundation for effective treatments for diabetes and obesity, and a driving force behind new therapeutic approaches for neurodegenerative diseases.